Optimizing immunotherapy for colorectal cancer.

Karuna Ganesh

Journal: Nature reviews. Gastroenterology & hepatology 2022;19(2):93-94

PMID: 34907331

Free Full Text on PubMed Central View on PubMed

Abstract

Important colorectal cancer (CRC) studies in 2021, including a new standard of care for first-line treatment of MSI-H–dMMR metastatic CRC, single-cell and spatial analysis of primary tumours and investigations of diet in preclinical models of cancer initiation, have provided novel insights into the CRC immune microenvironment.

Address: Molecular Pharmacology Program, Sloan Kettering Institute and Gastrointestinal Oncology Service, Memorial Hospital, Memorial Sloan Kettering Cancer Center, New York, NY, USA. [email protected].

DOI: 10.1038/s41575-021-00569-4

Link outs

Free resources

Full Text Sources:

Medical:

https://medlineplus.gov/colorectalcancer.html

Subscription / membership required

Full Text Sources:

https://doi.org/10.1038/s41575-021-00569-4

MeSH Terms: Antibodies, Monoclonal, Humanized, Antineoplastic Agents, Immunological, Colorectal Neoplasms, Humans, Immunotherapy, Tumor Microenvironment